search

Active clinical trials for "Lymphoma, Non-Hodgkin"

Results 1601-1610 of 1849

Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors...

Advanced Solid NeoplasmAggressive Non-Hodgkin Lymphoma4 more

The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab. We will also study how safely this combination of medication can be given in advanced cancer and lymphoma and benefits of receiving this therapy. Nivolumab is currently approved in certain cancers such as melanoma, lung cancer and kidney cancer. Veliparib is not yet approved for use in the United States, and is considered experimental. Veliparib inhibits (blocks) the activity of the enzyme PARP. This blocking activity may prevent the cancer cell from repairing itself and resume growing. Nivolumab increases T cells in your immune system, which allows your immune system to attack the cancer. We think the combination of these drugs will be more effective against your cancer.

Unknown status60 enrollment criteria

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory...

Relapsed or Refractory B Cell Non-Hodgkin LymphomaChronic Lymphocytic Leukemia4 more

This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM). The purpose of the study is to determine the MTD/RP2D of CT-1530, and evaluate its safety and tolerability as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).

Unknown status23 enrollment criteria

Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma

Recent literature data suggest beneficial effects of dietary fats in patients with cancers, in particular polyunsaturated fatty acids (PUFAs). Milled mix of flax, sesame and pumpkin seeds provides a high amount of PUFAs and a desirable n-6/n-3 PUFAs ratio.

Unknown status7 enrollment criteria

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory...

Non Hodgkin Lymphoma

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult subjects with relapsed and refractory B-cell Non-Hodgkin lymphoma.

Unknown status22 enrollment criteria

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating...

Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell Lymphoma10 more

This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax, carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow.

Unknown status22 enrollment criteria

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

B-cell Non-Hodgkin's Lymphoma

An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)

Unknown status37 enrollment criteria

MB-CART20.1 Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin's LymphomaNon-Hodgkin's Lymphoma2 more

This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.

Unknown status35 enrollment criteria

Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Non-Hodgkin Lymphoma

This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Non-Hodgkin lymphoma treatment.

Unknown status18 enrollment criteria

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Non Hodgkin Lymphoma

To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.

Unknown status28 enrollment criteria

A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

LymphomaFollicular

This is a study designed to evaluate the efficacy and safety of oral YY-20394 in patients with R/R follicular non-Hodgkin's lymphoma who have failed at least two prior systemic therapies.

Unknown status17 enrollment criteria
1...160161162...185

Need Help? Contact our team!


We'll reach out to this number within 24 hrs